Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy

被引:14
作者
Yamanaka, Hajime [1 ]
Goto, Ken-ichiro [1 ]
Miyamoto, Kazutoshi [1 ]
机构
[1] Shimoshizu Hosp, Natl Hosp Org, Dept Orthopaed Surg, Yotsukaido 2840003, Japan
关键词
TNF alpha; Infliximab; Etanercept; Rheumatoid arthritis; Synovium; Rooney's score; ETANERCEPT; INFLIXIMAB; EXPRESSION; METHOTREXATE; INFLAMMATION; APOPTOSIS; MEMBRANE; BLOCKADE;
D O I
10.1007/s00296-009-1158-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study was performed to evaluate the synovium in patients with rheumatoid arthritis (RA) treated with anti-tumor necrosis factor alpha agents (anti-TNF alpha). Synovial tissue specimens were obtained during total knee arthroplasty (TKA) from 42 RA patients (12 men, 30 women). Twenty-one RA patients were given anti-TNF alpha agents (infliximab, n = 12; etanercept, n = 9), while the remaining 21 RA patients were given no such agents. The histopathological findings were compared between specimens from these groups using the histological scoring system reported by Rooney, which consists of six items: degree of synovial hyperplasia, fibrosis, number of blood vessels, perivascular lymphocyte infiltration, focal aggregates of lymphocytes, and diffuse infiltrates of lymphocytes. Clinical laboratory data including C-reactive protein (CRP), matrix metalloproteinase-3 (MMP-3), and disease activity scores including a 28-joint count (DAS28), disease duration, methotrexate (MTX) dose, and glucocorticoid dose were also assessed before surgery. There were no significant differences in total score between anti-TNF alpha and no anti-TNF alpha groups. However, significant differences were observed in scores of synoviocyte hyperplasia and perivascular infiltrates of lymphocytes between the groups. These results suggested that these agents have a suppressive effect on cell proliferation in the lining layer and on perivascular lymphocyte infiltration. However, further studies are necessary to elucidate the mechanisms of these effects.
引用
收藏
页码:409 / 413
页数:5
相关论文
共 22 条
  • [1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [2] Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints - Extended report
    Catrina, AI
    Trollmo, C
    af Klint, E
    Engstrom, M
    Lampa, J
    Hermansson, Y
    Klareskog, L
    Ulfgren, AK
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (01): : 61 - 72
  • [3] Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis
    Catrina, AI
    Lampa, J
    Ernestam, S
    af Klint, E
    Bratt, J
    Klareskog, L
    Ulfgren, AK
    [J]. RHEUMATOLOGY, 2002, 41 (05) : 484 - 489
  • [4] Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
    Ernestam, S
    Klint, EA
    Catrina, AI
    Sundberg, E
    Engström, M
    Klareskog, L
    Ulfgren, K
    [J]. ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)
  • [5] FASSBENDER HG, 1975, PATHOLOGY RHEUMATIC, P79
  • [6] GARDNER DL, 1986, COPEMANS TXB RHEUMAT, V2, P604
  • [7] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Silman, Alan J.
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (01): : 13 - 20
  • [8] Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy
    Kruithof, E
    Baeten, D
    Van den Bosch, F
    Mielants, H
    Veys, EM
    De Keyser, F
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) : 529 - 536
  • [9] Infliximab and methotrexate in the treatment of rheumatoid arthritis
    Lipsky, PE
    van der Heijde, DMFM
    St Clair, EW
    Furst, DE
    Breedveld, FC
    Kalden, JR
    Smolen, JS
    Weisman, M
    Emery, P
    Feldmann, M
    Harriman, GR
    Maini, RN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
  • [10] MIELANTS H, 1991, J RHEUMATOL, V18, P1542